Theralase cancels $4.5M placement, arranges placement

Executive Summary

• Theralase Technologies Inc. has commenced a non-brokered private placement to raise up to $2 million, terminating a previously announced brokered financing with Research Capital Corp.
• Units are priced at 17 cents each, consisting of one common share and one common share purchase warrant, with a closing expected around the week of December 15, 2025.
• Proceeds will be used to fund the ongoing Phase II non-muscle invasive bladder cancer (NMIBC) clinical study and for general working capital.

Key Details

• Offering Size: Up to $2 million in gross proceeds.
• Unit Price: 17 cents per unit.
• Unit Composition: Each unit consists of one common share and one common share purchase warrant.
• Warrant Terms:
  • Entitles holder to purchase one common share.
  • Exercise Price: 21 cents per share.
  • Duration: 60 months following the closing date.
• Use of Proceeds: Furthering the Phase II non-muscle invasive bladder cancer (NMIBC) clinical study and working capital needs.
• Hold Period: Four months and one day from the closing date under applicable Canadian and US securities laws.
• Closing Date: Scheduled on or about the week of December 15, 2025, subject to necessary approvals including TSX Venture Exchange.
• Finder’s Fees:
  • Cash commission: 7% of gross proceeds.
  • Finder Warrants: Non-transferable warrants exercisable to acquire units equal to 7% of the total units issued.
  • Finder Warrant Exercise Price: 17 cents.
  • Finder Warrant Duration: 60 months following the closing date.
• Termination: Mutual termination of the previously announced brokered listed issuer financing exemption (LIFE) financing with Research Capital Corp.

Notable Quotes

• None provided in the text.